期刊文献+

蛋白酶体抑制剂诱导t(8;21)急性髓系白血病细胞凋亡

The Proteasome Inhibitor Induced Apoptosis of t ( 8 ; 21 ) Acute Myeloid Leukemia Cells
分享 导出
摘要 目的:探讨蛋白酶体抑制剂(PSI)对t(8;21)急性髓系白血病治疗的分子生物学机制。方法:t(8;21)白血病细胞Kasumi-1经5,8,10,25,50nmol/LPSI处理后,进行细胞计数和MTT检测,并且使用流式细胞分选和蛋白免疫印迹方法检测不同浓度的药物处理下细胞的调亡情况。结果:蛋白酶体抑制剂PSI诱导t(8;21)白血病细胞Kasumi-1在5~50nmol/L时间浓度梯度的自血病细胞调亡,以及对患者细胞有抑制增长作用,并发现随着药物作用时间的延长,表征凋亡的caspase.3条带的切割随之愈加的显著。这些结果表明,PSI诱导的细胞凋亡是通过caspase-3激活凋亡途径。结论:PSI可能是一个潜在的治疗t(8;21)白血病,并通过靶向AML1-ETO蛋白和激活凋亡通路治疗白血病的有效药物。 Objective To investigate the molecular biological mechanism of proteasome inhibitor (PSI) in treating t( 8;21 ) (q22 ;q22) acute myeloid leukemia(AML). Methods Kasumi-1 cells were treated with different concentrations (5,8,10, 25,50 nmol/L) of PSI for different times ,and the cell numbers were counted and the cell vitality were detected by MTT. The apoptosis of cells were detected by flow cytometry and Western blot. Results In the range from 5 to 50 nmol/L,PSI induced the cell apoptosis and inhbited the growth of Kasumi-1 cells in patients with AML, meanwhile the degradation band of caspase-3 protein representing cell apoptosis was more obviously induced following the prolongation of treatment time, suggesting that PSI induced apoptosis of AML cells through activating caspase-3 apoptotie pathways. Conclusion PSI may be a potential drug for treatment of t ( 8 ; 21 ) leukemia through targeting AML1 -ETO protein and activating caspase-3 apoptotie pathway.
作者 冯婷婷 秦宜德 刘莹 余贤军 FENG Ting-ting,QIN Yi-de,LIU Ying,YU Xian-jun(1.Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230001 ; 2. Department of Biochemistry, College of Basic Medicine, Hubei University of Medicine, Shiyan ;Hubei 442000, China)
出处 《湖北医药学院学报》 CAS 2015年第5期443-446,451共5页
基金 国家自然科学基金(30872992)
关键词 t(8 21)急性髓系白血病 蛋白酶体抑制剂 凋亡 t ( 8 21 ) leukemia Proteasome inhibitor Apoptosis
作者简介 冯婷婷(1982-),女,安徽合肥市人,硕士,研究方向:肿瘤分子生物学。
  • 相关文献

参考文献17

  • 1Abu-Arja RF, Chemin LR, Abusin G, et al. Successful hematopoietic cell transplantation in a patient with X- linked agobulinemia and acute myeloid leukemia [J]. Pediatr Blood Cancer,2015,62 (9) :1 674 - 1676. 被引量:1
  • 2Bartlett JR, Lunde JH. Acute myeloid leukemia pretrea- ted with filgrastim mimicking acute promyelocytic leu- kemia [ J ]. Blood, 2014,123 (25) : 3 853. 被引量:1
  • 3Delavigne K, Brard E, Bertoli S, et al. Hemophagocytic syndrome in patients with acute myeloid leukemia un- dergoing intensive chemotherapy [ J ]. Haematologica, 2014,99 ( 3 ) :474 - 480. 被引量:1
  • 4Cole A, Wang Z, Coyaud E, et al. Inhibition of the Mito- chondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia [ J ]. Cancer Cell, 2015,27(6) :864-876. 被引量:1
  • 5Martner A, Rydstrom A, Rebecca E Riise, et al. Natural Killer Cell Expression of Natural Cytotoxieity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with His- tamine Dihydrochloride and Interleukin-2 [ J ]. Blood, 2014,124(21 ) :3 680. 被引量:1
  • 6Ahmad A, Habeeb Z, A1-Mousa M, et al. Cancer Stem Cells, Therapeutic Implications [ J ]. Kuwait Medical Journal, 2015,47 (2) :97 - 114. 被引量:1
  • 7Choi YW, Park JS,Jung YS, et al. Faggot-like ceils ob- served in acute myeloid leukemia with myelodysplasia- related changes mimicking acute promyelocytic leuke- mia[ J]. Leuk Lymphoma,2015,56(6) : 1 906 - 1 907. 被引量:1
  • 8Busfield SJ, Biondo M, Wong M, et al. Targeting of a- cute myeloid leukemia in vitro and in vivo with an anti- CD123 mAb engineered for optimal ADCC [ J ]. Leuke- mia,2014,28(11) :2 213 -2 221. 被引量:1
  • 9Copelan EA. Leukemia cell mobilization:a road to erad- ication? [ J]. Bone Marrow Transplant, 2015,50 ( 7 ) : 905 - 906. 被引量:1
  • 10Cezar RS, Cerqueira BA, da Paz Sde S, et al. Outcome of B-Cell Acute Lymphoblastic Leukemia in Brazilian Children: Immunophenotypical, Hematological, and Clinical Evaluation [ J ]. J Pediatr Hematol Onco1,2015, 37(6) :423 -428. 被引量:1
投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈